메뉴 건너뛰기




Volumn 10, Issue 1, 2008, Pages 31-38

Managing Crohn disease in children and adolescents: Focus on tumor necrosis factor antagonists

Author keywords

Adalimumab, therapeutic use; Adolescents; CDP 571, therapeutic use; Certolizumab pegol, therapeutic use; Children; Crohn's disease, treatment; Etanercept, therapeutic use; Infliximab, therapeutic use; Research and development; Semapimod, therapeutic use

Indexed keywords

ADALIMUMAB; ADRENALIN; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; DIPHENHYDRAMINE; ETANERCEPT; HYDROCORTISONE; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; METHYLPREDNISOLONE; ONERCEPT; PARACETAMOL; SEMAPIMOD; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

EID: 37549047191     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200810010-00004     Document Type: Review
Times cited : (4)

References (73)
  • 1
    • 0024394527 scopus 로고
    • Incidence of inflammatory bowel disease in Scottish children between 1968 and 1983; marginal fall in ulcerative colitis, three fold rise in Crohn's disease
    • Barton JR, Gillon S, Ferguson A. Incidence of inflammatory bowel disease in Scottish children between 1968 and 1983; marginal fall in ulcerative colitis, three fold rise in Crohn's disease. Gut 1989; 30: 618-22
    • (1989) Gut , vol.30 , pp. 618-622
    • Barton, J.R.1    Gillon, S.2    Ferguson, A.3
  • 2
    • 0031019969 scopus 로고    scopus 로고
    • Inflammatory bowel diseases with onset in childhood. Clinical features, morbidity and mortality in a regional cohort
    • Langholz E, Munkholm P, Kraslinikoff PA, et al. Inflammatory bowel diseases with onset in childhood. Clinical features, morbidity and mortality in a regional cohort. Scand J Gastroenterol 1997; 32: 139-47
    • (1997) Scand J Gastroenterol , vol.32 , pp. 139-147
    • Langholz, E.1    Munkholm, P.2    Kraslinikoff, P.A.3
  • 3
    • 0242330303 scopus 로고    scopus 로고
    • Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: A state-wide population based study
    • Kugathasan S, Judd RH, Hoffman RG, et al. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a state-wide population based study. J Pediatr 2003; 143: 525-31
    • (2003) J Pediatr , vol.143 , pp. 525-531
    • Kugathasan, S.1    Judd, R.H.2    Hoffman, R.G.3
  • 4
    • 0033959385 scopus 로고    scopus 로고
    • Inflammatory bowel disease in Iceland, 1990-1994: A prospective, nationwide, epidemiological study
    • Bjornsson S, Johansson JH. Inflammatory bowel disease in Iceland, 1990-1994: a prospective, nationwide, epidemiological study. Eur J Gatroenterol Hepatol 2000; 12: 31-8
    • (2000) Eur J Gatroenterol Hepatol , vol.12 , pp. 31-38
    • Bjornsson, S.1    Johansson, J.H.2
  • 5
    • 0032981503 scopus 로고    scopus 로고
    • Inflammatory bowel disease in pediatric and adolescent patients
    • Baldassano RN, Piccoli DA. Inflammatory bowel disease in pediatric and adolescent patients. Gastroenterol Clin North Am 1999; 28: 445-58
    • (1999) Gastroenterol Clin North Am , vol.28 , pp. 445-458
    • Baldassano, R.N.1    Piccoli, D.A.2
  • 6
    • 0141682647 scopus 로고    scopus 로고
    • Inflammatory bowel disease in early childhood and adolescents: Special considerations
    • Mamula P, Markowitz JE, Baldassano RN. Inflammatory bowel disease in early childhood and adolescents: special considerations. Gastroenterol Clin North Am 2003; 32: 967-95
    • (2003) Gastroenterol Clin North Am , vol.32 , pp. 967-995
    • Mamula, P.1    Markowitz, J.E.2    Baldassano, R.N.3
  • 7
    • 0033227692 scopus 로고    scopus 로고
    • Romagnani S. Th1/Th2 cells. Inflamm Bowel Dis 1999; 5: 285-94
    • Romagnani S. Th1/Th2 cells. Inflamm Bowel Dis 1999; 5: 285-94
  • 8
    • 10044265135 scopus 로고    scopus 로고
    • Why do anti-tumor necrosis factor antibodies work in Crohn's disease?
    • Sands BE. Why do anti-tumor necrosis factor antibodies work in Crohn's disease? Rev Gastroenterol Disord 2004; 4 Suppl. 3: S10-7
    • (2004) Rev Gastroenterol Disord , vol.4 , Issue.SUPPL. 3
    • Sands, B.E.1
  • 9
    • 0033778364 scopus 로고    scopus 로고
    • Tumor necrosis factor: Biology and therapeutic inhibitors
    • Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000; 119: 1148-57
    • (2000) Gastroenterology , vol.119 , pp. 1148-1157
    • Papadakis, K.A.1    Targan, S.R.2
  • 10
    • 0031849974 scopus 로고    scopus 로고
    • Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites
    • Dieu MC, Vanbervliet B, Vicari A, et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 1998; 188: 373-86
    • (1998) J Exp Med , vol.188 , pp. 373-386
    • Dieu, M.C.1    Vanbervliet, B.2    Vicari, A.3
  • 11
    • 0026717674 scopus 로고
    • The pathophysiology of tumor necrosis factors
    • Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992; 10: 411-52
    • (1992) Annu Rev Immunol , vol.10 , pp. 411-452
    • Vassalli, P.1
  • 12
    • 0032522666 scopus 로고    scopus 로고
    • A p55 TNF receptor immunoadhesion prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production
    • Pender SL, Fell JM, Chamow SM, et al. A p55 TNF receptor immunoadhesion prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production. J Immunol 1998; 160: 4098-103
    • (1998) J Immunol , vol.160 , pp. 4098-4103
    • Pender, S.L.1    Fell, J.M.2    Chamow, S.M.3
  • 14
    • 0031596842 scopus 로고    scopus 로고
    • Methotrexate in patients with Crohn's disease after 6-mercaptopurine
    • Mack DR, Young R, Kaufmann SS, et al. Methotrexate in patients with Crohn's disease after 6-mercaptopurine. J Pediatr 1998; 132: 830-5
    • (1998) J Pediatr , vol.132 , pp. 830-835
    • Mack, D.R.1    Young, R.2    Kaufmann, S.S.3
  • 15
    • 0025009896 scopus 로고
    • Azathioprine in the treatment of children with inflammatory bowel disease
    • Verhave M, Winter HS, Grand RJ. Azathioprine in the treatment of children with inflammatory bowel disease. J Pediatr 1990; 117: 809-14
    • (1990) J Pediatr , vol.117 , pp. 809-814
    • Verhave, M.1    Winter, H.S.2    Grand, R.J.3
  • 16
    • 0031680256 scopus 로고    scopus 로고
    • Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease
    • Kirschner B. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998; 115: 813-21
    • (1998) Gastroenterology , vol.115 , pp. 813-821
    • Kirschner, B.1
  • 17
    • 0033761188 scopus 로고    scopus 로고
    • Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease
    • Kugathasan S, Werlin SL, Martinez A, et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000; 95: 3189-94
    • (2000) Am J Gastroenterol , vol.95 , pp. 3189-3194
    • Kugathasan, S.1    Werlin, S.L.2    Martinez, A.3
  • 18
    • 37549065631 scopus 로고    scopus 로고
    • A randomized controlled trial evaluating the ideal medical management for Crohn's disease (CD): 'top down' vs. 'step up' strategies
    • abstract no. W1017, May 14-19; Chicago IL
    • Hommes D, Baert F, van Assche G, et al. A randomized controlled trial evaluating the ideal medical management for Crohn's disease (CD): 'top down' vs. 'step up' strategies [abstract no. W1017]. Digestive Diseases Week conference; 2005 May 14-19; Chicago (IL)
    • (2005) Digestive Diseases Week conference
    • Hommes, D.1    Baert, F.2    van Assche, G.3
  • 19
    • 13944252969 scopus 로고    scopus 로고
    • Hepatosplenic T cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn's disease
    • Thayu M, Markowitz JE, Mamula P, et al. Hepatosplenic T cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn's disease. J Pediatr Gastroenterol Nutr 2005; 40: 220-2
    • (2005) J Pediatr Gastroenterol Nutr , vol.40 , pp. 220-222
    • Thayu, M.1    Markowitz, J.E.2    Mamula, P.3
  • 20
    • 0029004771 scopus 로고
    • Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions
    • Scallon BJ, Moore MA, Trinh H. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 1995; 7: 251-9
    • (1995) Cytokine , vol.7 , pp. 251-259
    • Scallon, B.J.1    Moore, M.A.2    Trinh, H.3
  • 21
    • 0038047689 scopus 로고    scopus 로고
    • Infliximab but not etanercept induces apoptosis in lamina propria T lymphocytes from patients with Crohn's disease
    • Van den Brande JM, Braat H, VanDen Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124: 1774-85
    • (2003) Gastroenterology , vol.124 , pp. 1774-1785
    • Van den Brande, J.M.1    Braat, H.2    VanDen Brink, G.R.3
  • 22
    • 17744373658 scopus 로고    scopus 로고
    • Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease
    • Cornillie F, Shealy D, D'Haens G, et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther 2001; 14: 463-73
    • (2001) Aliment Pharmacol Ther , vol.14 , pp. 463-473
    • Cornillie, F.1    Shealy, D.2    D'Haens, G.3
  • 23
    • 0038184193 scopus 로고    scopus 로고
    • Infliximab (Remicade) therapy in the treatment of pediatric Crohn's disease
    • Baldassano R, Braeger CP, Escher JC, et al. Infliximab (Remicade) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 2003; 98: 833-8
    • (2003) Am J Gastroenterol , vol.98 , pp. 833-838
    • Baldassano, R.1    Braeger, C.P.2    Escher, J.C.3
  • 24
    • 0033842357 scopus 로고    scopus 로고
    • Use of infliximab in the treatment of Crohn's disease in children and adolescents
    • Hyams JS, Markowitz J, Wylie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr 2000; 137: 192-6
    • (2000) J Pediatr , vol.137 , pp. 192-196
    • Hyams, J.S.1    Markowitz, J.2    Wylie, R.3
  • 25
    • 0037259135 scopus 로고    scopus 로고
    • Safety and steroid sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center
    • Stephens MC, Shepanski MA, Mamula P, et al. Safety and steroid sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol 2003; 98: 104-11
    • (2003) Am J Gastroenterol , vol.98 , pp. 104-111
    • Stephens, M.C.1    Shepanski, M.A.2    Mamula, P.3
  • 26
    • 9144234882 scopus 로고    scopus 로고
    • Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease
    • Lamireau T, Cezard JP, Dabadie A, et al. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. Inflamm Bowel Dis 2004; 10: 745-50
    • (2004) Inflamm Bowel Dis , vol.10 , pp. 745-750
    • Lamireau, T.1    Cezard, J.P.2    Dabadie, A.3
  • 27
    • 33748147712 scopus 로고    scopus 로고
    • Corticosteroid therapy in the age of infliximab: Acute and 1 year outcomes in newly diagnosed children with Crohn's disease
    • Markowitz J, Hyams J, Mack D, et al. Corticosteroid therapy in the age of infliximab: acute and 1 year outcomes in newly diagnosed children with Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1124-9
    • (2006) Clin Gastroenterol Hepatol , vol.4 , pp. 1124-1129
    • Markowitz, J.1    Hyams, J.2    Mack, D.3
  • 28
    • 0141613187 scopus 로고    scopus 로고
    • A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factor (Remicade®) in severe pediatric Crohn's disease
    • Cezard JP, Nouaili N, Talbotec C, et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factor (Remicade®) in severe pediatric Crohn's disease. J Pediatr Gastroenterol Nutr 2003; 36: 632-6
    • (2003) J Pediatr Gastroenterol Nutr , vol.36 , pp. 632-636
    • Cezard, J.P.1    Nouaili, N.2    Talbotec, C.3
  • 29
    • 14644440656 scopus 로고    scopus 로고
    • Infliximab therapy in 30 patients with refractory pediatric Crohn's disease with and without fistulas in The Netherlands
    • de Ridder L, Escher JC, Bouquet J, et al. Infliximab therapy in 30 patients with refractory pediatric Crohn's disease with and without fistulas in The Netherlands. J Pediatr Gastroenterol Nutr 2004; 39: 46-52
    • (2004) J Pediatr Gastroenterol Nutr , vol.39 , pp. 46-52
    • de Ridder, L.1    Escher, J.C.2    Bouquet, J.3
  • 30
    • 0042329252 scopus 로고    scopus 로고
    • Response to infliximab is related to disease duration in paediatric Crohn's disease
    • Lionetti P, Bronzini F, Salvestrini C, et al. Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther 2003; 18: 425-31
    • (2003) Aliment Pharmacol Ther , vol.18 , pp. 425-431
    • Lionetti, P.1    Bronzini, F.2    Salvestrini, C.3
  • 31
    • 0034108994 scopus 로고    scopus 로고
    • Azathioprine and 6-meracptopurine for the treatment of perianal Crohn's disease in children
    • Jeshion WC, Larsen KL, Jawad AF, et al. Azathioprine and 6-meracptopurine for the treatment of perianal Crohn's disease in children. J Clin Gastroenterol 2000; 30: 294-8
    • (2000) J Clin Gastroenterol , vol.30 , pp. 294-298
    • Jeshion, W.C.1    Larsen, K.L.2    Jawad, A.F.3
  • 32
    • 0024244814 scopus 로고
    • Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease
    • Kanof M, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease. Gastroenterology 1988; 95: 1523-7
    • (1988) Gastroenterology , vol.95 , pp. 1523-1527
    • Kanof, M.1    Lake, A.M.2    Bayless, T.M.3
  • 33
    • 4544305960 scopus 로고    scopus 로고
    • Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease
    • Borrelli O, Bascietto C, Viola F, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis 2004; 36: 342-7
    • (2004) Dig Liver Dis , vol.36 , pp. 342-347
    • Borrelli, O.1    Bascietto, C.2    Viola, F.3
  • 34
    • 30344431805 scopus 로고    scopus 로고
    • Infliximab dependency in a national cohort of children with Crohn's disease
    • Wewer V, Riis L, Vind I, et al. Infliximab dependency in a national cohort of children with Crohn's disease. J Pediatr Gastroenterol Nutr 2006; 42: 40-5
    • (2006) J Pediatr Gastroenterol Nutr , vol.42 , pp. 40-45
    • Wewer, V.1    Riis, L.2    Vind, I.3
  • 35
    • 37549042126 scopus 로고    scopus 로고
    • Pathogenesis of immunological/inflammatory GI disease and IBD [abstract no. 86]
    • Benkov KJ, Vorha P, Pittman NS, et al. Pathogenesis of immunological/inflammatory GI disease and IBD [abstract no. 86]. J Pediatr Gastroenterol Nutr 1996; 23: 363
    • (1996) J Pediatr Gastroenterol Nutr , vol.23 , pp. 363
    • Benkov, K.J.1    Vorha, P.2    Pittman, N.S.3
  • 36
    • 0033770169 scopus 로고    scopus 로고
    • A multicenter trial of 6-mercaptopurine and prednisone with newly diagnosed Crohn's disease
    • Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone with newly diagnosed Crohn's disease. Gastroenterology 2000; 119: 895-902
    • (2000) Gastroenterology , vol.119 , pp. 895-902
    • Markowitz, J.1    Grancher, K.2    Kohn, N.3
  • 38
    • 33947397636 scopus 로고    scopus 로고
    • Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children
    • Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007; 132: 863-73
    • (2007) Gastroenterology , vol.132 , pp. 863-873
    • Hyams, J.1    Crandall, W.2    Kugathasan, S.3
  • 39
    • 0037247042 scopus 로고    scopus 로고
    • Infusion reactions to infliximab in children and adolescents: Frequency, outcome and a predictive model
    • Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 2003; 17: 75-84
    • (2003) Aliment Pharmacol Ther , vol.17 , pp. 75-84
    • Crandall, W.V.1    Mackner, L.M.2
  • 41
    • 0038649858 scopus 로고    scopus 로고
    • The incidence and management of infusion reactions to infliximab: A large center experience
    • Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98: 1315-24
    • (2003) Am J Gastroenterol , vol.98 , pp. 1315-1324
    • Cheifetz, A.1    Smedley, M.2    Martin, S.3
  • 42
    • 10744224387 scopus 로고    scopus 로고
    • Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease
    • Rutgeerts P, Feagan BG, Lichtenstein G, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402-13
    • (2004) Gastroenterology , vol.126 , pp. 402-413
    • Rutgeerts, P.1    Feagan, B.G.2    Lichtenstein, G.3
  • 43
    • 14044252848 scopus 로고    scopus 로고
    • Adalimumab induces apoptosis of human monocytes: A comparative study with infliximab and etanercept
    • Shen C, Assche GV, Colpaert S, et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 2005; 21: 251-8
    • (2005) Aliment Pharmacol Ther , vol.21 , pp. 251-258
    • Shen, C.1    Assche, G.V.2    Colpaert, S.3
  • 44
    • 33645651405 scopus 로고    scopus 로고
    • Drug insight: Antagonists of tumor necrosis factor-α in the treatment of inflammatory bowel disease
    • Chang JT, Lichtenstein GR. Drug insight: antagonists of tumor necrosis factor-α in the treatment of inflammatory bowel disease. Nat Clin Pract 2006; 3: 220-8
    • (2006) Nat Clin Pract , vol.3 , pp. 220-228
    • Chang, J.T.1    Lichtenstein, G.R.2
  • 45
    • 32044451548 scopus 로고    scopus 로고
    • Human anti tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I Trial
    • Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I Trial. Gastroenterology 2006; 130: 323-33
    • (2006) Gastroenterology , vol.130 , pp. 323-333
    • Hanauer, S.B.1    Sandborn, W.J.2    Rutgeerts, P.3
  • 46
    • 29444442072 scopus 로고    scopus 로고
    • Maintenance of remission over 1 year in patients with active Crohn's disease treated with adalimumab: Results of a blinded, placebo-controlled study [abstract no. 843]
    • S
    • Sandborn WJ, Hanauer SB, Lukas M, et al. Maintenance of remission over 1 year in patients with active Crohn's disease treated with adalimumab: results of a blinded, placebo-controlled study [abstract no. 843]. Am J Gastroenterol 2005; 100 Suppl. S: S311
    • (2005) Am J Gastroenterol , vol.100 , Issue.SUPPL.
    • Sandborn, W.J.1    Hanauer, S.B.2    Lukas, M.3
  • 47
    • 33846242958 scopus 로고    scopus 로고
    • Adalimumab for maintenance of clinical response in patients with Crohn's disease: The CHARM Trial
    • Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response in patients with Crohn's disease: the CHARM Trial. Gastroenterol 2007; 132: 52-65
    • (2007) Gastroenterol , vol.132 , pp. 52-65
    • Colombel, J.F.1    Sandborn, W.J.2    Rutgeerts, P.3
  • 48
    • 7044226437 scopus 로고    scopus 로고
    • An open label study of the human anti-tnf monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease
    • Sandborn WJ, Hanauer S, Loftus EV, et al. An open label study of the human anti-tnf monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004; 99: 1984-9
    • (2004) Am J Gastroenterol , vol.99 , pp. 1984-1989
    • Sandborn, W.J.1    Hanauer, S.2    Loftus, E.V.3
  • 49
    • 37549047302 scopus 로고    scopus 로고
    • Hinojosa J, Gomollon F, Nos P, et al. Four week results of adalimumab treatment in subjects with fistulizing Crohn's disease who have failed response or showed intolerance to infliximab [abstract no. 815]. Digestive Diseases Week; 2006 May 19-24; Los Angeles (CA)
    • Hinojosa J, Gomollon F, Nos P, et al. Four week results of adalimumab treatment in subjects with fistulizing Crohn's disease who have failed response or showed intolerance to infliximab [abstract no. 815]. Digestive Diseases Week; 2006 May 19-24; Los Angeles (CA)
  • 50
    • 24644445063 scopus 로고    scopus 로고
    • Adalimumab, a novel anti-tumor necrosis factor-alpha antibody in a child with refractory Crohn's disease
    • Mian S, Baron H. Adalimumab, a novel anti-tumor necrosis factor-alpha antibody in a child with refractory Crohn's disease. J Pediatr Gastroenterol Nutr 2005; 41 (3): 357-9
    • (2005) J Pediatr Gastroenterol Nutr , vol.41 , Issue.3 , pp. 357-359
    • Mian, S.1    Baron, H.2
  • 51
    • 0034800239 scopus 로고    scopus 로고
    • Surpassing conventional therapies: The role of biologic therapy
    • Baldassano RN. Surpassing conventional therapies: the role of biologic therapy. J Pediatr Gastroenterol Nutr 2001; 33: S19-26
    • (2001) J Pediatr Gastroenterol Nutr , vol.33
    • Baldassano, R.N.1
  • 52
    • 4344702394 scopus 로고    scopus 로고
    • Recent advances in biological therapy for inflammatory bowel disease
    • Kurtovic J, Segal I. Recent advances in biological therapy for inflammatory bowel disease. Trop Gastroenterol 2004; 25: 9-14
    • (2004) Trop Gastroenterol , vol.25 , pp. 9-14
    • Kurtovic, J.1    Segal, I.2
  • 53
    • 4644325814 scopus 로고    scopus 로고
    • CDP571, a humanized monoclonal antibody to tumor necrosis factor ?, for moderate to severe Crohn's disease: A randomized, double blind, placebo controlled trial
    • Sandborn WJ, Feagan BG, Radford-Smith G, et al. CDP571, a humanized monoclonal antibody to tumor necrosis factor ?, for moderate to severe Crohn's disease: a randomized, double blind, placebo controlled trial. Gut 2004; 53: 1485-93
    • (2004) Gut , vol.53 , pp. 1485-1493
    • Sandborn, W.J.1    Feagan, B.G.2    Radford-Smith, G.3
  • 54
    • 9144261186 scopus 로고    scopus 로고
    • CDP-571, a humanized anti tumor necrosis factor ? monoclonal antibody in pediatric Crohn's disease
    • Mamula P, Cohen SA, Ferry GA, et al. CDP-571, a humanized anti tumor necrosis factor ? monoclonal antibody in pediatric Crohn's disease. Inflamm Bowel Dis 2004; 10: 723-30
    • (2004) Inflamm Bowel Dis , vol.10 , pp. 723-730
    • Mamula, P.1    Cohen, S.A.2    Ferry, G.A.3
  • 55
    • 0026080801 scopus 로고
    • Thalidomide selectively inhibits tumor necrosis factor ? production by stimulated human monocytes
    • Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor ? production by stimulated human monocytes. J Exp Med 1991; 173: 699-703
    • (1991) J Exp Med , vol.173 , pp. 699-703
    • Sampaio, E.P.1    Sarno, E.N.2    Galilly, R.3
  • 56
    • 0035071241 scopus 로고    scopus 로고
    • Efficacy of long-term treatment with thalidomide in children and young adults with Crohn's disease: Preliminary results
    • Facchini S, Candusso M, Martelossi S, et al. Efficacy of long-term treatment with thalidomide in children and young adults with Crohn's disease: preliminary results. J Pediatr Gastroenterol Nutr 2001; 32: 178-81
    • (2001) J Pediatr Gastroenterol Nutr , vol.32 , pp. 178-181
    • Facchini, S.1    Candusso, M.2    Martelossi, S.3
  • 57
    • 33749424855 scopus 로고    scopus 로고
    • Treatment with thalidomide in children and adolescents with inflammatory bowel disease
    • Martelossi S, Marchetti F, Lenhardt A, et al. Treatment with thalidomide in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2004; 39: S282
    • (2004) J Pediatr Gastroenterol Nutr , vol.39
    • Martelossi, S.1    Marchetti, F.2    Lenhardt, A.3
  • 58
    • 24144483087 scopus 로고    scopus 로고
    • A randomized placebo-controlled trial of certolizumab pegol (CDP 870) for treatment of Crohn's disease
    • Schreiber S, Rutgeerts P, Fedorak R, et al. A randomized placebo-controlled trial of certolizumab pegol (CDP 870) for treatment of Crohn's disease. Gastroenterology 2005; 129: 807-18
    • (2005) Gastroenterology , vol.129 , pp. 807-818
    • Schreiber, S.1    Rutgeerts, P.2    Fedorak, R.3
  • 59
    • 33144489771 scopus 로고    scopus 로고
    • Certolizumab pegol, a humanized anti-TNF pegylated FAb' fragment, is safe, and effective in the maintenance of response and remission following induction in active Crohn's disease: A phase III study (PRECiSE)
    • Schreiber S, Khaliq-Kareemi M, Lawrence I, et al. Certolizumab pegol, a humanized anti-TNF pegylated FAb' fragment, is safe, and effective in the maintenance of response and remission following induction in active Crohn's disease: a phase III study (PRECiSE). Gut 2005; 54 Suppl. VII: A82
    • (2005) Gut , vol.54 , Issue.SUPPL. VII
    • Schreiber, S.1    Khaliq-Kareemi, M.2    Lawrence, I.3
  • 60
    • 0037315157 scopus 로고    scopus 로고
    • Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumor necrosis factor receptor): Results of a randomized, open label, pilot study
    • Rutgeerts P, Lemmens L, Van Assche G, et al. Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumor necrosis factor receptor): results of a randomized, open label, pilot study. Aliment Pharmacol Ther 2003; 17: 185-92
    • (2003) Aliment Pharmacol Ther , vol.17 , pp. 185-192
    • Rutgeerts, P.1    Lemmens, L.2    Van Assche, G.3
  • 61
    • 33745608448 scopus 로고    scopus 로고
    • Onercept for moderate to severe Crohn's disease: A randomized, double blind, placebo controlled trial
    • Rutgeerts P, Sandborn WJ, Fedorak RN, et al. Onercept for moderate to severe Crohn's disease: a randomized, double blind, placebo controlled trial. Clin Gastroenterol Hepatol 2006; 4: 888-93
    • (2006) Clin Gastroenterol Hepatol , vol.4 , pp. 888-893
    • Rutgeerts, P.1    Sandborn, W.J.2    Fedorak, R.N.3
  • 62
    • 0034827790 scopus 로고    scopus 로고
    • Etanercept in the treatment of active refractory Crohn's disease: A single center pilot trial
    • D'Haens G, Swijsen C, Norman M, et al. Etanercept in the treatment of active refractory Crohn's disease: a single center pilot trial. Am J Gastroenterol 2001; 96: 2564-8
    • (2001) Am J Gastroenterol , vol.96 , pp. 2564-2568
    • D'Haens, G.1    Swijsen, C.2    Norman, M.3
  • 63
    • 0034754477 scopus 로고    scopus 로고
    • Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
    • Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121: 1088-94
    • (2001) Gastroenterology , vol.121 , pp. 1088-1094
    • Sandborn, W.J.1    Hanauer, S.B.2    Katz, S.3
  • 64
    • 0036142395 scopus 로고    scopus 로고
    • Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease
    • Hommes D, van den Blink B, Plasse T, et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 2002; 122: 7-14
    • (2002) Gastroenterology , vol.122 , pp. 7-14
    • Hommes, D.1    van den Blink, B.2    Plasse, T.3
  • 65
    • 33646147141 scopus 로고    scopus 로고
    • Serious infections and mortality in association with therapies for Crohn's disease: TREAT Registry
    • Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT Registry. Clin Gastroenterol Hepatol 2006; 4: 621-30
    • (2006) Clin Gastroenterol Hepatol , vol.4 , pp. 621-630
    • Lichtenstein, G.R.1    Feagan, B.G.2    Cohen, R.D.3
  • 66
    • 37549046504 scopus 로고    scopus 로고
    • Remicade® (infliximab) prescribing information. Malvern (PA): Centocor Inc., 2007
    • Remicade® (infliximab) prescribing information. Malvern (PA): Centocor Inc., 2007
  • 67
    • 34247504544 scopus 로고    scopus 로고
    • Risks and benefits of biologic therapy for inflammatory bowel diseases
    • D' Haens G. Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut 2007; 56: 725-32
    • (2007) Gut , vol.56 , pp. 725-732
    • D' Haens, G.1
  • 68
    • 37549010039 scopus 로고    scopus 로고
    • Surveillance, Epidemiology, and End Results Database (SEER) program. SEER incidence crude rates, 11 Registries, 1993-2001. Rockville (MD): National Cancer Institute
    • Surveillance, Epidemiology, and End Results Database (SEER) program. SEER incidence crude rates, 11 Registries, 1993-2001. Rockville (MD): National Cancer Institute
  • 69
    • 37549059671 scopus 로고    scopus 로고
    • Humira® (adalimumab) prescribing information. Chicago (IL): Abbott Laboratories, 2007
    • Humira® (adalimumab) prescribing information. Chicago (IL): Abbott Laboratories, 2007
  • 70
    • 37549031823 scopus 로고    scopus 로고
    • Remicade® (infliximab) for IV injection prescribing information. Malvern (PA): Centocor Inc., 2007
    • Remicade® (infliximab) for IV injection prescribing information. Malvern (PA): Centocor Inc., 2007
  • 71
    • 33646696885 scopus 로고    scopus 로고
    • Anti TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancy. Systematic review and meta-analysis of rare harmful effects in randomized controlled trials
    • Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancy. Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 296: 2275-85
    • (2006) JAMA , vol.296 , pp. 2275-2285
    • Bongartz, T.1    Sutton, A.J.2    Sweeting, M.J.3
  • 72
    • 34347369156 scopus 로고    scopus 로고
    • Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: A cautionary tale?
    • Rosh JR, Gross T, Mamula P, et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis 2007; 13 (8): 1024-30
    • (2007) Inflamm Bowel Dis , vol.13 , Issue.8 , pp. 1024-1030
    • Rosh, J.R.1    Gross, T.2    Mamula, P.3
  • 73
    • 33846592386 scopus 로고    scopus 로고
    • Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease
    • Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44: 265-7
    • (2007) J Pediatr Gastroenterol Nutr , vol.44 , pp. 265-267
    • Mackey, A.C.1    Green, L.2    Liang, L.C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.